AnthonyFShieldsMDPhD

Oncology • Detroit, MI

Gastrointestinal Cancer

Associate Center Director, Karmanos Cancer Institute, Professor of Oncology, Wayne State University

Join to view full profile

Dr. Shields is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shields' full profile

Already have an account?

Office
4100 John R Street, HW04HO
Karmanos Cancer Institute
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8767

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1984
University of WashingtonResidency, Internal Medicine, 1979 - 1981
Massachusetts Institute of TechnologyPhD, Biology, 1973 - 1979
Harvard Medical SchoolClass of 1979

Certifications & Licensure

MI State Medical License 1995 - 2027
WA State Medical License 1980 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy Start of enrollment: 2007 Mar 30
Terminated
Not Applicable
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
Suspended
Not Applicable
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Start of enrollment: 2011 Aug 17
Completed
Phase 1
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy Start of enrollment: 2012 Jun 01
Completed
Not Applicable
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Completed
Not Applicable
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2016 May 16
Recruiting
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Start of enrollment: 2020 Jan 07
Terminated
Phase 1, Phase 2
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Start of enrollment: 2018 Jun 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Start of enrollment: 2018 Oct 24
Terminated
Phase 1
Roles: Contact
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography Start of enrollment: 2016 Jun 01
Active, not recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer
Journal of Immunotherapy and Precision Oncology. 2025-02-01
Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma.
Bach Ardalan, Aaron Ciner, Yasmine Baca, Andrew Hinton, Sourat Darabi
Clinical Cancer Research. 2025-01-16
1 citations
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes.
Pooja Mittal, Francesca Battaglin, Yasmine Baca, Joanne Xiu, Alex Farrell
International Journal of Cancer. 2024-12-30

Press Mentions

Karmanos Cancer Institute Physicians Begin Prescribing New FDA-Approved Radiofrequency Electromagnetic Device to Treat Advanced Liver CancerDecember 18th, 2024
Karmanos Cancer Institute Receives $630,000 CATCH-UP Grant to Recruit Minority and Rural Patients to Clinical TrialsAugust 25th, 2020
OncLive® Presents State of the Science Summit™ on Gastrointestinal MalignanciesApril 23rd, 2019
Join now to see all

Grant Support

Imaging Cellular Stress And Treatment Response Using Positron Emission TomographyNational Cancer Institute2010–2012
Develpmental TherapeuticsNational Cancer Institute2005–2009
Labeled Thymidine -- Development As A PET Imaging AgentNational Cancer Institute2004–2008
Labeled Thymidine-Development As A PET Imaging AgentNational Cancer Institute2005–2006
Midcareer Investigator AwardNational Cancer Institute1999–2003
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1997–2003
Developmental TherapeuticsNational Cancer Institute2001–2002
PET Imaging Of Drug Kinetics And PathwaysNational Cancer Institute1999–2002
Metabolic Measurement In Lymphoma Treated With ChemotherapyNational Cancer Institute1996–1997
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1988–1994
Labeled Thymidine: Development As A PET Imaging AgentNational Cancer Institute1987–1993
Labeled Thymidine--Development As A PET Imaging AgentNational Cancer Institute1985–1987